Sign in

You're signed outSign in or to get full access.

John Scott

Chief Strategy Officer at Innventure
Executive

About John Scott

Dr. John Scott, 74, serves as Innventure’s Chief Strategy Officer; he has held the CSO role at Innventure LLC since 2015 and previously founded and led XL TechGroup, developing the DownSelect methodology Innventure uses to vet technologies . He holds a Ph.D. in Physics and Astrophysics from the University of Arizona and has published over 60 academic papers, with prior academic appointments and work at NASA Goddard . His 2024 incentive design tied pay to strategic milestones and business KPIs (e.g., new operating company formation, business combination proceeds, Accelsius and AeroFlexx revenue thresholds), with an 85% bonus achievement determined in 2025 contingent on continued service . Company-wide TSR, revenue growth or EBITDA growth metrics for executive pay are not disclosed in proxies reviewed .

Past Roles

OrganizationRoleYearsStrategic Impact
XL TechGroup (XLTG)Founder & CEO1993–2013Created DownSelect method to commercialize MNC-sourced technologies
Universities/NASA GoddardAcademic ScientistNot disclosedResearch and publication history (>60 papers)

External Roles

No current public company directorships or external committee roles for Dr. Scott are disclosed in the proxies reviewed .

Fixed Compensation

Component20242023Notes
Base salary/service fees ($)$300,000 $300,000 2024 paid via Corporate Development Group (consulting)
Base/service fee change (effective Jan 2025)$37,500 per month ($450,000 annualized) Increase approved January 2025
Perquisites (aircraft reimbursements)$122 (2024) $216 (2023) Time-sharing agreements with partial aircraft interest

Performance Compensation

MetricWeightTargetActualPayout DeterminationVesting/Timing
Formation of a new 4th operating company25% Company forms new OpCoYes Counted toward 85% achievement; $255,000 notionally earned of $300,000 target, contingent on continued service and future payment disclosure Cash bonus payout timing not disclosed; determination made in 2025
Complete Business Combination with >$20m net proceeds50% Net proceeds >$20mYes Included in 85% achievement
Milestone: 4th OpCo formation (duplicate milestone)10% Formation milestoneYes Included in 85% achievement
Accelsius booked revenue10% $10m booked revenueNo Reduces payout; overall 85% achievement
AeroFlexx GAAP revenue5% $15m GAAP revenueNo Reduces payout; overall 85% achievement
Stretch goal: formation of a 5th operating company+50% potential New 5th OpCoNot achieved No incremental payout

Equity Awards and Vesting

Award TypeGrant DetailsQuantityEconomicsVesting/Exercise Terms
RSUs (Company)December 2024336,066 Grant date fair value included in 2024 stock awards $4,100,005 Vests Oct 2, 2025, or earlier upon lock-up termination; accelerated vesting upon death, disability or change-in-control per RSU agreement
Stock Options (Company)December 2024163,934 Exercise price $12.20; 2024 option award fair value $6,935,489 Vests Oct 2, 2025, or earlier upon lock-up termination
Accelsius SARs (Settled in common shares)December 2024; amended June 25, 2025150,000 SARs Base price $12.175; share-settled with a maximum of 1,875,000 shares per officer; automatic exercise at 24 months, death or disability
Refinity Holdings PI Units (profits interests)December 11, 2024109,000 PI Units Participates in distributions above a threshold; grant FV $0 Vests over 3 years: 25% at 1-year anniversary, 9.375% quarterly thereafter, subject to continued service

Equity Ownership & Alignment

As of Oct 6, 2025Common Shares OwnedOptions/RSUs Exercisable within 60 daysTotal Beneficial Ownership% of Common Outstanding
John Scott2,417,719 163,934 (options vested Oct 2, 2025) 2,581,653 4.46% (based on 57,920,864 shares outstanding)
  • Hedging/pledging policy: Company prohibits hedging and discourages pledging or margining of company stock; standing/limit orders are discouraged, per the Insider Trading Policy and governance disclosures . No pledging by Dr. Scott is disclosed in reviewed filings .
  • 10b5-1 plans: In Q2 2025, aside from one director, no directors or officers adopted, modified, or terminated Rule 10b5-1 or non-Rule plans; this implies Dr. Scott did not adopt or modify a plan in that quarter .

Employment Terms

  • Role and arrangement: Dr. Scott provides CSO services via Corporate Development Group LLC; 2024 service fees were $25,000 per month ($300,000 annualized), increased to $37,500 per month effective January 2025 .
  • Lock-ups: Certain insiders entered lock-up agreements at the business combination; restrictions lapse at the earlier of one year post-closing (Oct 2, 2025) or achievement of a $12 price threshold for 20 of 30 days after 150 days; RSUs/options for Dr. Scott were structured to vest at lock-up expiration or earlier upon its termination .
  • Clawback: A “no-fault” clawback policy (Nasdaq Rule 5608) was adopted in Oct 2024; upon certain accounting restatements, incentive-based compensation excess must be recovered from Section 16 officers for the prior three fiscal years .
  • Change-of-Control terms: RSUs vest in full upon a change-in-control, death, or disability under the RSU agreement; options/SARs follow their award-specific terms (SARs auto-exercise on specified events) .
  • Related party transactions:
    • Bridge note: Innventure borrowed $2,000 from Dr. Scott on Aug 22, 2024; amended Oct 1, 2024 to $1,000 principal with 13.5% interest; on Mar 20, 2025, repaid via $195 cash and issuance of 226,334 Series C Preferred shares on Mar 24, 2025 .
    • Aircraft time-sharing: Innventure reimbursed Dr. Scott $122 in 2024 under an aircraft time-sharing agreement; initial term one year, auto-renewing monthly .

Multi-Year Compensation (NEO disclosure)

YearSalary/Service Fees ($)Bonus ($)Stock Awards ($)Option Awards ($)All Other Compensation ($)Total ($)
2024300,000 4,100,005 6,935,489 11,335,494
2023300,000 180,000 480,000

Investment Implications

  • Alignment and ownership: Scott’s 4.46% beneficial stake and significant vested awards (RSUs, options, SARs) align interests but introduce potential supply overhang around Oct 2, 2025 lock-up expiration and award settlement dates; no 10b5-1 plan was adopted in Q2 2025, which could increase discretionary selling risk absent later plan adoption .
  • Incentive structure: 2024 bonus metrics emphasize milestone execution (new OpCo formation, capital raising via business combination), with operational revenue targets for Accelsius and AeroFlexx partially missed; compensation tilt toward equity (RSUs/options/SARs/PI Units) increases sensitivity to share price and subsidiary value creation .
  • Governance and red flags: Related party bridge financing (equity-for-debt exchanges) and aircraft reimbursements are disclosed and governed by audit committee oversight; insider hedging is prohibited and pledging discouraged, reducing misalignment risks, and a clawback policy mitigates restatement risk exposure on incentives .
  • Retention dynamics: The consulting arrangement and increased 2025 service fee suggest retention investment; RSU change-of-control acceleration provides protection but could accelerate payouts in a transaction, affecting post-deal retention incentives without additional arrangements disclosed .